Market News & Trends
MilliporeSigma Signs Exclusive Agreement With BioDuro
MilliporeSigma has signed a supply and OEM agreement with BioDuro, LLC, on exclusive terms, for worldwide distribution of AISF ([4-(Acetylamino)phenyl]-ImidodiSulfuryl diFluoride), a convenient, shelf-stable, crystalline…
Sienna Biopharmaceuticals Announces Topical Drug Study Results
Sienna Biopharmaceuticals, Inc. recently announced top-line results from a Phase 2b study of SNA-120 (pegcantratinib), the company’s lead drug candidate developed using its proprietary Topical…
Melissa Unlocks Insight & Revenue With Breakthrough AI Tools for Clinics & Research Centers
Melissa, a leading provider of global contact data quality and identity verification solutions, recently announced advanced artificial intelligence (AI) solutions that combine machine reasoning, natural…
GSK to Acquire Oncology Focused Biopharmaceutical Company
GlaxoSmithKline plc recently announced that the companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology focused company based…
SELLAS Life Sciences Announces Completion of Enrollment in Phase 2 Randomized Controlled Clinical Study
SELLAS Life Sciences Group, Inc. recently announced the completion of enrollment for a Phase 2 independent investigator-sponsored clinical trial of the combination of trastuzumab (Herceptin)…
Opthea Confirms Final Patient Enrolment in Phase 2b Wet AMD Clinical Trial
Opthea Limited recently announced the last patient has been enrolled in the company’s ongoing Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD),…
Novo Nordisk Announces Phase 3a Results Using Emisphere’s Technology
Novo Nordisk recently announced the completion and results regarding its Pioneer 9 and Pioneer 6 Phase 3a trials, both conducted with oral semaglutide, a once-daily…
CBT Pharmaceuticals & Zhejiang Bossan Pharmaceutical Enter Collaboration & License Agreement
CBT Pharmaceuticals (CBT) and Zhejiang Bossan Pharmaceutical Co., Ltd (Bossan) recently announced they have entered into a clinical collaboration and license agreement to develop their…
Dalton Pharma Services Enters Drug Development & Manufacturing Services Agreement
Dalton Pharma Services recently announce a drug development and manufacturing services agreement with ExCellThera Inc. This agreement provides ExCellThera access to Dalton’s state-of-the-art cGMP, Health…
Edge Therapeutics Enters Into Merger Agreement With PDS Biotechnology
Edge Therapeutics, Inc. and PDS Biotechnology Corporation recently announced their respective boards of directors have approved a definitive merger agreement. The merger is expected to…